Mersana Therapeutics (STU:0M4) Cash Flow for Lease Financing : €0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Mersana Therapeutics Cash Flow for Lease Financing?

Mersana Therapeutics's Cash Flow for Lease Financing for the three months ended in Mar. 2024 was €0.00 Mil. Mersana Therapeutics's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil.

Compared with last quarter (€0.00 Mil in Dec. 2023 ), Mersana Therapeutics's Cash Flow for Lease Financing remained the same in Mar. 2024 (€0.00 Mil).

Mersana Therapeutics Cash Flow for Lease Financing Historical Data

The historical data trend for Mersana Therapeutics's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mersana Therapeutics Cash Flow for Lease Financing Chart

Mersana Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Flow for Lease Financing

Get a 7-Day Free Trial

Mersana Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash Flow for Lease Financing	Get a 7-Day Free Trial															-	-	-	-	-

Mersana Therapeutics Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.

Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Mersana Therapeutics Cash Flow for Lease Financing Related Terms

Thank you for viewing the detailed overview of Mersana Therapeutics's Cash Flow for Lease Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Mersana Therapeutics (STU:0M4) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mersana Therapeutics Inc (STU:0M4) » Definitions » Cash Flow for Lease Financing

Comparable Companies

Traded in Other Exchanges

MRSN:USA 0M4:Germany

Address

840 Memorial Drive, Cambridge, MA, USA, 02139

Website

https://www.mersana.com

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.

Mersana Therapeutics (STU:0M4) Headlines

No Headlines